CSL, Arcturus Therapeutics announce Japan MHLW approval for Kostaive

CSL (CSLLY) and Arcturus Therapeutics (ARCT) announced that Japan’s Ministry of Health, Labor and Welfare, or MHLW, granted approval and authorization for their updated self-amplifying mRNA COVID-19 vaccine, Kostaive. The updated vaccine is targeted to protect against the JN.1 lineage of Omicron subvariants for adults 18 years of age and older. CSL’s exclusive partner in Japan, Meiji Seika Pharma, will begin distributing the updated vaccine in time for the October COVID-19 vaccination campaign, marking the world’s first commercially available sa-mRNA COVID-19 vaccine for adults 18 and older. In May, a Japanese health ministry panel recommended that COVID-19 vaccines be updated to target the JN.1 lineage of Omicron subvariants for the 2024/2025 national immunization program. This aligns with recent recommendations from the World Health Organization.